Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation

BACKGROUND: The use of Anti-PD-1 therapy has yielded promising outcomes in hepatocellular carcinoma (HCC). However, limited research has been conducted on the overall survival (OS) of patients with varying tumor responses and treatment duration. METHODS: This retrospective study analyzed HCC patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Kang, Xiang, Yan-Jun, Yu, Hong-Ming, Cheng, Yu-Qiang, Feng, Jin-Kai, Liu, Zong-Han, Shan, Yun-Feng, Zheng, Yi-Tao, Ni, Qian-Zhi, Cheng, Shu-Qun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591394/
https://www.ncbi.nlm.nih.gov/pubmed/37867191
http://dx.doi.org/10.1186/s12885-023-11485-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591394/
https://www.ncbi.nlm.nih.gov/pubmed/37867191
http://dx.doi.org/10.1186/s12885-023-11485-y

Ejemplares similares